Neumora Therapeutics IPO Presentation Deck
Building a Company with the Scale and Scope to Address the
Brain Disease Crisis for Patients
Company Built
at Scale with
Differentiated
Approach
Pipeline
of Novel
Mechanisms
●
●
●
●
●
●
●
●
●
Raised >$600M to date from leading investors and collaborators, including Series B close in Oct. 2022
Led by experienced company builders and leading neuroscience drug developers
Precision approach leveraging unique data sciences capability underlying development strategy
Strong capital position to support growth with compelling use of proceeds story for proposed offering
Strategy supported by long-dated composition of matter patents for each of our programs, into 2041+
Portfolio of seven clinical and preclinical programs targeting novel mechanisms of action, with large therapeutic and
commercial potential creating rich set of catalysts
Lead program, navacaprant (KOR antagonist) demonstrated positive Phase 2 clinical data and is currently in Phase
3 trials with topline data expected in 2H 2024
Mid-stage clinical program, NMRA-511 (V1aR antagonist) expected to enter AD agitation studies in 1H 2024
IND submission planned for NMRA-266 (M4 PAM) in the fourth quarter of 2023
Deep preclinical pipeline with near-IND assets focused on Parkinson's, ALS and other indications
Confidential
27View entire presentation